Grandbrothers/iStock Editorial via Getty Images Biomea Fusion ( NASDAQ: BMEA ) shares were up 8% in afternoon trading after it said the FDA had lifted the clinical hold on a Phase 1/2 study of its drug BMF-219 for the treatment of type 1 and type 2 diabetes. The.
Back to Health Page
